Phibro Animal Health Corporation (NASDAQ:PAHC) Receives Average Rating of “Hold” from Analysts

Shares of Phibro Animal Health Corporation (NASDAQ:PAHC) have been assigned a consensus recommendation of “Hold” from the eight ratings firms that are presently covering the firm, MarketBeat.com reports. Two equities research analysts have rated the stock with a sell rating, three have given a hold rating, two have assigned a buy rating and one has given a strong buy rating to the company. The average 12-month price objective among brokers that have covered the stock in the last year is $31.40.

A number of analysts have recently commented on the company. JPMorgan Chase & Co. upped their target price on Phibro Animal Health from $45.00 to $50.00 and gave the stock an “overweight” rating in a research note on Friday, November 7th. Weiss Ratings restated a “buy (b-)” rating on shares of Phibro Animal Health in a research report on Monday. Finally, Zacks Research raised shares of Phibro Animal Health from a “hold” rating to a “strong-buy” rating in a report on Tuesday, December 9th.

Phibro Animal Health Stock Down 0.4%

PAHC stock opened at $37.36 on Friday. The company has a market capitalization of $1.51 billion, a P/E ratio of 22.51, a price-to-earnings-growth ratio of 1.06 and a beta of 0.79. Phibro Animal Health has a 12 month low of $16.16 and a 12 month high of $46.42. The firm’s fifty day simple moving average is $41.17 and its 200-day simple moving average is $35.89. The company has a debt-to-equity ratio of 2.32, a current ratio of 3.09 and a quick ratio of 1.35.

Phibro Animal Health (NASDAQ:PAHC) last issued its earnings results on Wednesday, November 5th. The company reported $0.73 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.58 by $0.15. Phibro Animal Health had a net margin of 4.85% and a return on equity of 36.26%. The firm had revenue of $363.89 million during the quarter, compared to analysts’ expectations of $345.44 million. Phibro Animal Health has set its FY 2026 guidance at 2.640-2.810 EPS. As a group, equities research analysts forecast that Phibro Animal Health will post 1.95 earnings per share for the current year.

Phibro Animal Health Dividend Announcement

The company also recently disclosed a quarterly dividend, which was paid on Wednesday, December 17th. Shareholders of record on Wednesday, November 26th were issued a $0.12 dividend. The ex-dividend date of this dividend was Wednesday, November 26th. This represents a $0.48 dividend on an annualized basis and a yield of 1.3%. Phibro Animal Health’s payout ratio is presently 28.92%.

Insider Activity

In other news, CEO Jack Bendheim sold 5,752 shares of the firm’s stock in a transaction dated Thursday, December 11th. The stock was sold at an average price of $40.93, for a total transaction of $235,429.36. Following the sale, the chief executive officer directly owned 39,200 shares in the company, valued at $1,604,456. This trade represents a 12.80% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Over the last 90 days, insiders have sold 146,554 shares of company stock worth $6,338,444. Corporate insiders own 50.13% of the company’s stock.

Hedge Funds Weigh In On Phibro Animal Health

Large investors have recently bought and sold shares of the business. JPMorgan Chase & Co. grew its holdings in Phibro Animal Health by 1,730.9% in the third quarter. JPMorgan Chase & Co. now owns 238,115 shares of the company’s stock valued at $9,634,000 after purchasing an additional 225,110 shares during the period. Tudor Investment Corp ET AL lifted its position in shares of Phibro Animal Health by 3.4% during the 3rd quarter. Tudor Investment Corp ET AL now owns 10,184 shares of the company’s stock valued at $412,000 after buying an additional 338 shares in the last quarter. Danske Bank A S acquired a new stake in Phibro Animal Health in the 3rd quarter valued at $955,000. Advisory Services Network LLC purchased a new stake in Phibro Animal Health in the 3rd quarter worth $96,000. Finally, Dark Forest Capital Management LP purchased a new stake in Phibro Animal Health in the 3rd quarter worth $2,751,000. Institutional investors and hedge funds own 99.34% of the company’s stock.

About Phibro Animal Health

Phibro Animal Health Corporation (NASDAQ: PAHC) is a diversified global animal health and mineral nutrition company headquartered in Teaneck, New Jersey. The company develops, manufactures and markets a broad range of pharmaceutical, mineral nutrition and performance products designed to support the health and productivity of livestock, companion animals and aquaculture species. Phibro’s portfolio includes vaccines, anti-infective therapies, coccidiostats, disinfectants, premix minerals and specialty feed additives aimed at enhancing growth, immunity and overall animal well-being.

The company operates through three principal business segments: Animal Health, Mineral Nutrition and Performance Products.